Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Pfizer Inc (PFE)

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 204,271,056
  • Shares Outstanding, K 5,558,396
  • Annual Sales, $ 51,750 M
  • Annual Income, $ 16,273 M
  • 60-Month Beta 0.70
  • Price/Sales 4.25
  • Price/Cash Flow 8.97
  • Price/Book 3.15
Trade PFE with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 0.52
  • Number of Estimates 7
  • High Estimate 0.66
  • Low Estimate 0.34
  • Prior Year 0.55
  • Growth Rate Est. (year over year) -5.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.27 +1.20%
on 01/04/21
38.47 -4.59%
on 12/16/20
-2.00 (-5.18%)
since 12/15/20
3-Month
34.60 +6.08%
on 10/29/20
43.08 -14.80%
on 12/09/20
+0.16 (+0.42%)
since 10/15/20
52-Week
27.88 +31.65%
on 03/23/20
43.08 -14.80%
on 12/09/20
-3.96 (-9.75%)
since 01/15/20

Most Recent Stories

More News
The Latest: UN chief: Solidarity needed to vaccinate nations

UNITED NATIONS — The United Nations chief is urging the world to mark the “heart-wrenching milestone” of 2 million deaths from the coronavirus by acting with greater solidarity to ensure vaccines...

PFE : 36.72 (-0.08%)
Pfizer temporarily reduces European deliveries of vaccine

COPENHAGEN, Denmark (AP) — U.S. pharmaceutical company Pfizer confirmed Friday it will temporarily reduce deliveries to Europe of its COVID-19 vaccine while it upgrades production capacity to 2 billion...

PFE : 36.72 (-0.08%)
Thinking about trading options or stock in Axon Enterprise, Tilray, Pfizer, Crispr Therapeutics, or General Motors?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAXN, TLRY, PFE, CRSP, and GM.

AAXN : 150.69 (+0.70%)
CRSP : 201.08 (-4.27%)
TLRY : 19.78 (+6.57%)
GM : 50.13 (-2.72%)
PFE : 36.72 (-0.08%)
Pfizer's (PFE) Xalkori Gets FDA Nod for Rare Lymphoma in Kids

FDA approves Pfizer's (PFE) Xalkori for relapsed or refractory ALK-positive anaplastic large cell lymphoma, a rare form of non-Hodgkin lymphoma (NHL), in pediatric patients and young adults.

ALXN : 156.58 (-0.04%)
RHHBY : 44.5900 (+1.46%)
PFE : 36.72 (-0.08%)
MRK : 83.29 (+1.36%)
Pharma Stock Roundup: LLY's Alzheimer Disease Data, NVS & SNY's M&A Deals

Lilly's (LLY) candidate, donanemab shows slowing of cognitive decline in Alzheimer's disease patients. Novartis (NVS) and Sanofi (SNY) announce M&A deals.

SNY : 49.17 (+0.29%)
RHHBY : 44.5900 (+1.46%)
PFE : 36.72 (-0.08%)
MRK : 83.29 (+1.36%)
LLY : 191.00 (+2.31%)
GSK : 38.40 (+0.63%)
NVS : 95.55 (+0.98%)
Pfizer's XALKORI(R) (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for XALKORI(R) (crizotinib) for the treatment of pediatric...

PFE : 36.72 (-0.08%)
Exact Sciences (EXAS) Posts Solid Preliminary Q4 Testing Revenues

Exact Sciences' (EXAS) strength in Screening revenue along with a robust COVID-19 testing arm are likely to have boosted the top line significantly.

PFE : 36.72 (-0.08%)
HOLX : 76.02 (-0.60%)
IDXX : 487.95 (-0.19%)
EXAS : 144.90 (-1.62%)
Why Pfizer (PFE) Could Beat Earnings Estimates Again

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

PFE : 36.72 (-0.08%)
Sarepta (SRPT) Inks New Gene Editing Research Collaboration

Sarepta (SRPT) signs agreement with Genevant to develop lipid nanoparticle-based gene editing medicines targeting neuromuscular indications.

RHHBY : 44.5900 (+1.46%)
PFE : 36.72 (-0.08%)
SRPT : 90.58 (+0.76%)
SLDB : 6.59 (+2.01%)
Global PCOS (Polycystic Ovary Syndrome) Treatment Markets, Forecast & Opportunities, 2025

, /PRNewswire/ -- The report has been added to offering.

ABT : 111.18 (+1.04%)
BAYRY : 15.8175 (-1.39%)
BMY : 66.60 (+0.88%)
MRK : 83.29 (+1.36%)
NVS : 95.55 (+0.98%)
PFE : 36.72 (-0.08%)
TEVA : 11.96 (+4.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Key Turning Points

3rd Resistance Point 37.29
2nd Resistance Point 37.12
1st Resistance Point 36.94
Last Price 36.72
1st Support Level 36.59
2nd Support Level 36.42
3rd Support Level 36.24

See More

52-Week High 43.08
Fibonacci 61.8% 37.27
Last Price 36.72
Fibonacci 50% 35.48
Fibonacci 38.2% 33.69
52-Week Low 27.88

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar